Jade Biosciences, Inc. (JBIO) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 9K | 0 | 0 | 0 | 8K | 0 | 28K | 28K | 28K | 25K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -9K | 0 | 0 | 0 | -8K | 0 | -28K | -28K | -28K | -25K |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | - | 100% | 71.43% | 100% | - | - | - | - |
| Operating Expenses | 43.44M | 34.98M | 27.4M | 27.78M | 6.39M | 14.96M | 26.14M | 24.59M | 22.04M | 21.34M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 7.38M | 6.44M | 5.39M | 5.23M | 4.86M | 1.38M | 4.89M | 4.51M | 4.22M | 4.46M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 36.05M | 28.54M | 22.01M | 22.55M | 1.53M | 13.58M | 21.25M | 20.08M | 17.81M | 16.88M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -43.45M | -34.98M | -27.4M | -27.78M | -6.4M | -14.96M | -26.16M | -24.62M | -22.07M | -21.37M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -446.29% | -83.1% | -6.16% | 70.98% | 29.97% | - | - | - | - |
| EBITDA | -43.44M | -34.97M | -27.39M | -27.78M | -6.39M | -16.28M | -26.14M | -24.59M | -22.04M | -21.34M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -446.83% | -68.27% | -6.28% | 70.98% | 23.74% | - | - | - | - |
| D&A (Non-Cash Add-back) | 9K | 9K | 12K | 0 | 8K | 0 | 28K | 28K | 28K | 25K |
| EBIT | -43.45M | -34.98M | -27.4M | -27.78M | -5.38M | -16.28M | -24.77M | -23.19M | -20.36M | -19.56M |
| Net Interest Income | 3.1M | 3.08M | 2.25M | 1.83M | 1.03M | 388K | 1.4M | 1.44M | 1.71M | 1.8M |
| Interest Income | 3.1M | 3.08M | 2.25M | 1.83M | 1.03M | 388K | 1.4M | 1.44M | 1.71M | 1.8M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 3.09M | 3.1M | 2.23M | -4.36M | 1.03M | -1.31M | 1.39M | 1.43M | 1.71M | 1.8M |
| Pretax Income | -40.35M | -31.87M | -25.18M | -32.13M | -5.38M | -16.28M | -24.77M | -23.19M | -20.36M | -19.56M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 16K | 58K | 0 | 0 | 55K | 0 | 0 | 0 | 56K | 0 |
| Effective Tax Rate % | -0.04% | -0.18% | 0% | 0% | -1.02% | 0% | 0% | 0% | -0.28% | 0% |
| Net Income | -40.37M | -31.93M | -25.18M | -32.13M | -5.43M | -16.28M | -24.77M | -23.19M | -20.41M | -19.56M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -488.07% | -54.67% | -29.7% | 73.4% | 16.8% | - | - | - | - |
| Net Income (Continuing) | -40.37M | -31.93M | -25.18M | -32.13M | -5.43M | -16.28M | -24.77M | -23.19M | -20.41M | -19.56M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.70 | -0.65 | -0.64 | -1.13 | -6.56 | -5.16 | -30.15 | -29.20 | -25.80 | -24.77 |
| EPS Growth % | - | 90.09% | 87.59% | 96.25% | 74.58% | 79.18% | - | - | - | - |
| EPS (Basic) | -0.70 | -0.45 | -0.64 | -1.13 | -6.56 | -5.16 | -30.15 | -29.20 | -25.80 | -24.77 |
| Diluted Shares Outstanding | 57.78M | 49.32M | 39.58M | 28.43M | 828.14K | 3.16M | 821.6K | 794.17K | 791.29K | 789.73K |
| Basic Shares Outstanding | 57.78M | 70.79M | 39.58M | 28.43M | 828.14K | 3.16M | 821.6K | 794.17K | 791.29K | 789.73K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |